Base and Prime Editing Technologies for Blood Disorders
Open Access
- 28 January 2021
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Genome Editing
- Vol. 3
Abstract
Nuclease-based genome editing strategies hold great promise for the treatment of blood disorders. However, a major drawback of these approaches is the generation of potentially harmful double strand breaks (DSBs). Base editing is a CRISPR-Cas9-based genome editing technology that allows the introduction of point mutations in the DNA without generating DSBs. Two major classes of base editors have been developed: cytidine base editors or CBEs allowing C>T conversions and adenine base editors or ABEs allowing A>G conversions. The scope of base editing tools has been extensively broadened, allowing higher efficiency, specificity, accessibility to previously inaccessible genetic loci and multiplexing, while maintaining a low rate of Insertions and Deletions (InDels). Base editing is a promising therapeutic strategy for genetic diseases caused by point mutations, such as many blood disorders and might be more effective than approaches based on homology-directed repair, which is moderately efficient in hematopoietic stem cells, the target cell population of many gene therapy approaches. In this review, we describe the development and evolution of the base editing system and its potential to correct blood disorders. We also discuss challenges of base editing approaches–including the delivery of base editors and the off-target events–and the advantages and disadvantages of base editing compared to classical genome editing strategies. Finally, we summarize the recent technologies that have further expanded the potential to correct genetic mutations, such as the novel base editing system allowing base transversions and the more versatile prime editing strategy.Keywords
This publication has 106 references indexed in Scilit:
- Programmable editing of a target base in genomic DNA without double-stranded DNA cleavageNature, 2016
- CRISPRs for Optimal Targeting: Delivery of CRISPR Components as DNA, RNA, and Protein into Cultured Cells and Single-Cell EmbryosHuman Gene Therapy, 2016
- In vivo genome editing using Staphylococcus aureus Cas9Nature, 2015
- Seamless gene correction of β-thalassemia mutations in patient-specific iPSCs using CRISPR/Cas9 and piggyBacGenome Research, 2014
- Analysis of risk factors influencing outcomes after cord blood transplantation in children with juvenile myelomonocytic leukemia: a EUROCORD, EBMT, EWOG-MDS, CIBMTR studyBlood, 2013
- A Distinctive DNA Damage Response in Human Hematopoietic Stem Cells Reveals an Apoptosis-Independent Role for p53 in Self-RenewalCell Stem Cell, 2010
- In vivo selection of genetically modified erythroblastic progenitors leads to long-term correction of β-thalassemiaProceedings of the National Academy of Sciences, 2008
- Hb G-MAKASSAR [β6(A3)Glu→Ala; CODON 6 (GAG→GCG)]: MOLECULAR CHARACTERIZATION, CLINICAL, AND HEMATOLOGICAL EFFECTSHemoglobin, 2002
- Phenotype—genotype relationships in monogenic disease: lessons from the thalassaemiasNature Reviews Genetics, 2001
- Molecular Basis of Hereditary Persistence of Fetal HemoglobinAnnals of the New York Academy of Sciences, 1998